Contact sales for details.
Mounjaro has superior persistence compared to Ozempic, especially when indicated to treat type II diabetes, according to Earnest pharmacy claims data. Around 62% of type II diabetes patients on Mounjaro continue on therapy 12 months out from their initial prescription, compared to around 45% for the same cohort of patients on Ozempic. Across both drugs, persistence rates among patients on GLP-1 therapy for obesity is meaningfully lower relative to the type II diabetes cohort. The limited number of patients using Mounjaro off-label for obesity is roughly on par with Ozempic persistence for type II diabetes, hovering around 45% at month 12. Ozempic persistence among obesity users was 35% at the 12 month mark.
Novo Nordisk’s Wegovy was excluded from this analysis as recurrent supply shortages drove volatility in patients’ ability to remain on therapy.
Increased adoption of the semaglutide-based GLP-1’s like Mounjaro and Ozempic could also impact consumer markets like restaurants and CPG.
Data Disclaimer:
Results reflect data as of December 7th, 2023 when they were prepared. Current results may have changed due to panel and methodology updates.
